Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 9, 2009, Pages 1295-1301

  Schnitzler, Fabian ^a   Fidder, Herma ^a   Ferrante, Marc ^a   Noman, Maja ^a   Arijs, Ingrid ^a   Van Assche, Gert ^a   Hoffman, Ilse ^a   Van Steen, Kristel ^b   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Changing disease course; Crohn's disease; Infliximab; Long term endoscopic outcome; Mucosal healing

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSAL HEALING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT RESPONSE; ADOLESCENT; ADULT; COHORT ANALYSIS; DRUG EFFECT; FOLLOW UP; MUCOSA; PROGNOSIS; TIME; TREATMENT OUTCOME; WOUND HEALING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MUCOUS MEMBRANE; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 70350172248     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20927     Document Type: Article

References (18)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. (Pubitemid 34784976)
2. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782. (Pubitemid 33096034)
3. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharm Ther. 2006;25:3-12. (Pubitemid 44902859)
4. Frøslie KF, Jahnsen J, Moum BA, et al and the IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
5. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442. (Pubitemid 43261469)
6. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56;453-455.
7. Venkateshan SP, Sidhu S, Malhotra S, et al. Efficacy of biologicals in the treatment of rheumatoid arthritis. A meta-analysis. Pharmacology. 2008;83:1-9.
8. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475-1481. (Pubitemid 27181370)
9. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50:667-671. (Pubitemid 29518050)
10. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
11. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. (Pubitemid 40139240)
12. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
13. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut. 1990;31:325-328. (Pubitemid 20093672)
14. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034. (Pubitemid 29203012)
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
16. Van Assche G, Madelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868. (Pubitemid 351790744)
17. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomised, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut. 2008;57(Suppl II):A1.-
18. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut. 2008 (in press).